Evidence map›Paper›PMID 28360821›Full record

ArticleCancer cell international2017

Combined EphB2 receptor knockdown with radiation decreases cell viability and invasion in medulloblastoma.

Shilpa Bhatia, Kellen Hirsch, Sanjana Bukkapatnam, Nimrah A Baig, Ayman Oweida, Anastacia Griego, Dylan Calame, Jaspreet Sharma, Andrew Donson, Nicholas Foreman and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The Roles of EphB2 in Cancer.Frontiers in cell and developmental biology · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Shilpa Bhatia *Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, CO 80045 USA.
Kellen Hirsch *Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, CO 80045 USA.
Sanjana BukkapatnamSchool of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO 80045 USA.
Nimrah A BaigDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057 USA.
Ayman OweidaDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, CO 80045 USA.
Anastacia GriegoDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, CO 80045 USA.
Dylan CalameSchool of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO 80045 USA.
Jaspreet SharmaDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, CO 80045 USA.
Andrew DonsonDepartment of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO 80045 USA.
Nicholas ForemanDepartment of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO 80045 USA.
Christopher AlbaneseDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057 USA.
Sujatha VenkataramanDepartment of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO 80045 USA.
Rajeev VibhakarDepartment of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO 80045 USA.
Sana D KaramDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, CO 80045 USA.
University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · USChildren's Hospital Colorado · USGeorgetown University · USGeorgetown University Medical Center · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5M
Training in Translational Research of Lung, Head and Neck CancerT32CA174648 · NCI · UNIVERSITY OF COLORADO DENVER · PI KARAM, SANA D · 2013 to 2022
$4.2M
NCI NIH HHS P30 CA046934NCI NIH HHS P30 CA051008NCI NIH HHS T32 CA174648
6 · The paper itself

Abstract

backgroundMedulloblastoma is one of the most common types of pediatric brain tumor characterized by the subpopulation of cells that exhibit high invasive potential and radioresistant properties. In addition, dysregulated function and signaling by Eph family of receptors have been shown to impart pro-tumorigenic characteristics in this brain malignancy. In the current study, we investigated whether EphB2 knockdown in combination with radiation can alter invasiveness and decrease medulloblastoma tumor growth or viability in vitro.

methodsThe expression of EphB2 receptor was analyzed by immunohistochemistry and Western blotting. Microarray analysis and mRNA analysis was performed on medulloblastoma patient datasets and compared to the normal cerebellum. The radiosensitization effect following EphB2 knockdown was determined by clonogenic assay in human medulloblastoma cells. Effects of EphB2-siRNA in absence or presence of radiation on cell cycle distribution, cell viability, and invasion were analyzed by flow cytometry, MTT assay, trypan blue exclusion assay, xcelligence system, and Western blotting.

resultsWe observed that EphB2 is expressed in both medulloblastoma cell lines and patient samples and its downregulation sensitized these cells to radiation as evident by decreased clonogenic survival fractions. EphB2 expression was also high across different medulloblastoma subgroups compared to normal cerebellum. The radiosensitization effect observed following EphB2 knockdown was in part mediated by enhanced G2/M cell cycle arrest. We also found that the combined approach of EphB2 knockdown and radiation exposure significantly reduced overall cell viability in medulloblastoma cells compared to control groups. Similar results were obtained in the xcelligence-based invasion assay. Western blot analysis also demonstrated changes in the protein expression of cell proliferation, cell survival, and invasion molecules in the combination group versus others.

conclusionsOverall, our findings indicate that specific targeting of EphB2 receptor in combination with radiation may serve as an effective therapeutic strategy in medulloblastoma. Future studies are warranted to test the efficacy of this approach in in vivo preclinical models.

Indexed as

EphB2InvasionMedulloblastomaRadiosensitization

Identifiers

PMID28360821
PMCPMC5371267
OpenAlexW2600562279

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.